• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Oncology division





























He gone! Was in way over his head. Was never a decent rep, a mediocre manager. Total fish out of water in da dirty South!
Ok, most people in the South are in way over their heads. But was there an hr/policy violation? You don’t get dismissed in 9 months when you’re learning how to get out of being over your head.
 












Will the last person here please turn off the lights
and light a candle
Tonight I'm in a romantic mood, yeah
Let's take a shower, said a shower together, yes
I'll wash your body and you'll wash mine, yeah
Rub me down in some, some hot oils, baby
And I'll do the same thing to you

Just turn off the lights, come to me
Girl, I wanna give you a special treat, you're so sweet
Turn off the lights, let's get cozy
See, you're the only one in the world that I need
 












At least someone did something! This is a nightmare. I bet 1/2 of oncology is let go in the spring, then they will try to figure out what to do. Our product is finished. It doesn't work well and there is nothing for years to come.


Eisai oncology rep are the absolute bottom of the barrel…primary care talent at best.

No Onc rep who knows anything about anything says, “yeah man, Eisai Oncology is where I want to be”.

Mediocre product, pod selling with Merck, primary care culture, no equity and low comp package…literally the worst.
 
















Lung- Failed
Melanoma- Nothing
HCC- Left behind by competition
Bladder- Left behind by competition
That leaves DTC and that's a big market.
Oh yea, we have big things coming- WHEN? We are at the end and I see nothing coming. This is why Eisai has a revolving door, people leave and we hire and train them and they leave..... I think in March, we will be sorry we stayed. Merck is about to drop us.
 




Lung- Failed
Melanoma- Nothing
HCC- Left behind by competition
Bladder- Left behind by competition
That leaves DTC and that's a big market.
Oh yea, we have big things coming- WHEN? We are at the end and I see nothing coming. This is why Eisai has a revolving door, people leave and we hire and train them and they leave..... I think in March, we will be sorry we stayed. Merck is about to drop us.

Don’t forget about getting our asses handed to us in RCC.